TY - JOUR
T1 - Impact of type of thrombolytic agent on in-hospital outcomes in ST-segment elevation myocardial infarction patients in the Middle East
AU - Al-Zakwani, Ibrahim
AU - Ali, Amr
AU - Zubaid, Mohammad
AU - Panduranga, Prashanth
AU - Sulaiman, Kadhim
AU - Abusham, Ahmed
AU - Almahmeed, Wael
AU - Al-Motarreb, Ahmed
AU - Suwaidi, Jassim Al
AU - Amin, Haitham
N1 - Funding Information:
Acknowledgments Gulf RACE was sponsored by the Gulf Heart Association and was financially supported by a grant from Sanofi Aventis and Qatar Telecommunications Company. The financial sponsors had no role in study design, data collection, data analysis, writing of the report or submission of the manuscript. The authors declare no conflicts of interest with respect to the authorship and/or publication of this article. The authors would like to thank the patients, physicians, nurses, and support staff who participated in Gulf RACE registry for their invaluable contribution and cooperation.
PY - 2012/4
Y1 - 2012/4
N2 - Little is known about the impact of thrombolytic agents on in-hospital outcomes in the Middle East. The objective of this study was to evaluate the impact of thrombolytic agents on in-hospital outcomes in ST-segment elevation myocardial infarction (STEMI) patients in six Middle Eastern countries. Gulf Registry of Acute Coronary Events was a prospective, multinational, multicentre, observational survey of consecutive acute coronary syndrome patients admitted to 65 hospitals in 2006 and 2007. Out of 1,765 STEMI patients admitted to hospitals within 12 h of symptoms onset, 25, 43, and 30% were treated with streptokinase, reteplase, and tenecteplase, respectively. Median age of the study cohort was 50 (45-59) years and majority were males (89%). The overall median symptom onset-to-presentation andmedian door-to-needle times were 130 min (65-240) and 45 min (30-75), respectively. Streptokinase patients had worse GRACE risk scores compared to patients who received fibrin specific thrombolytics. Academic hospitals and cardiologists as admitting physicians were associated with the use of fibrin specific thrombolytics. After significant covariate adjustment, both reteplase >odds ratio (OR), 0.38; 95% CI: 0.18-0.79; P = 0.009] and tenecteplase (OR, 0.30; 95% CI: 0.12-0.77; P = 0.012) were associated with lower allcause in-hospital mortality compared with streptokinase. No significant differences in other in-hospital outcomes were noted between the thrombolytic agents. In conclusion, in light of the study's limitations, fibrin specific agents, reteplase and tenecteplase, were associated with lower all-cause in-hospital mortality compared to the non-specific fibrin agent, streptokinase. However, the type of thrombolytic agent used did not influence other in-hospital outcomes.
AB - Little is known about the impact of thrombolytic agents on in-hospital outcomes in the Middle East. The objective of this study was to evaluate the impact of thrombolytic agents on in-hospital outcomes in ST-segment elevation myocardial infarction (STEMI) patients in six Middle Eastern countries. Gulf Registry of Acute Coronary Events was a prospective, multinational, multicentre, observational survey of consecutive acute coronary syndrome patients admitted to 65 hospitals in 2006 and 2007. Out of 1,765 STEMI patients admitted to hospitals within 12 h of symptoms onset, 25, 43, and 30% were treated with streptokinase, reteplase, and tenecteplase, respectively. Median age of the study cohort was 50 (45-59) years and majority were males (89%). The overall median symptom onset-to-presentation andmedian door-to-needle times were 130 min (65-240) and 45 min (30-75), respectively. Streptokinase patients had worse GRACE risk scores compared to patients who received fibrin specific thrombolytics. Academic hospitals and cardiologists as admitting physicians were associated with the use of fibrin specific thrombolytics. After significant covariate adjustment, both reteplase >odds ratio (OR), 0.38; 95% CI: 0.18-0.79; P = 0.009] and tenecteplase (OR, 0.30; 95% CI: 0.12-0.77; P = 0.012) were associated with lower allcause in-hospital mortality compared with streptokinase. No significant differences in other in-hospital outcomes were noted between the thrombolytic agents. In conclusion, in light of the study's limitations, fibrin specific agents, reteplase and tenecteplase, were associated with lower all-cause in-hospital mortality compared to the non-specific fibrin agent, streptokinase. However, the type of thrombolytic agent used did not influence other in-hospital outcomes.
KW - Hospital mortality
KW - Middle East
KW - Myocardial infarction
KW - Reteplase
KW - Streptokinase
KW - Tenecteplase
KW - Thrombolytic therapy
UR - http://www.scopus.com/inward/record.url?scp=84871685754&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871685754&partnerID=8YFLogxK
U2 - 10.1007/s11239-012-0698-6
DO - 10.1007/s11239-012-0698-6
M3 - Article
C2 - 22359050
AN - SCOPUS:84871685754
SN - 0929-5305
VL - 33
SP - 280
EP - 286
JO - Journal of Thrombosis and Thrombolysis
JF - Journal of Thrombosis and Thrombolysis
IS - 3
ER -